Poltreg S.A. (PTG.WA)
PLN 34.5
(0.29%)
PLN 34.5
(0.29%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -57.75 Million PLN | 29.68% |
| 2022 | -82.13 Million PLN | 20.84% |
| 2021 | -103.76 Million PLN | -626.28% |
| 2020 | -14.28 Million PLN | -355.73% |
| 2019 | -3.13 Million PLN | 18.21% |
| 2018 | -3.83 Million PLN | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -46.32 Million PLN | 6.33% |
| 2024 Q1 | -49.45 Million PLN | 14.38% |
| 2023 Q1 | -72.43 Million PLN | 11.81% |
| 2023 FY | -57.75 Million PLN | 29.68% |
| 2023 Q2 | -67.85 Million PLN | 6.33% |
| 2023 Q4 | -57.75 Million PLN | 19.71% |
| 2023 Q3 | -71.93 Million PLN | -6.01% |
| 2022 Q2 | -102.55 Million PLN | 2.66% |
| 2022 Q1 | -105.36 Million PLN | -1.54% |
| 2022 Q3 | -89.61 Million PLN | 12.62% |
| 2022 FY | -82.13 Million PLN | 20.84% |
| 2022 Q4 | -82.13 Million PLN | 8.35% |
| 2021 Q1 | -15.75 Million PLN | -10.28% |
| 2021 Q4 | -103.76 Million PLN | -696.58% |
| 2021 Q3 | -13.02 Million PLN | 8.32% |
| 2021 FY | -103.76 Million PLN | -626.28% |
| 2021 Q2 | -14.2 Million PLN | 9.82% |
| 2020 Q4 | -14.28 Million PLN | 0.0% |
| 2020 FY | -14.28 Million PLN | -355.73% |
| 2020 Q1 | 5.17 Million PLN | 0.0% |
| 2019 FY | -3.13 Million PLN | 18.21% |
| 2018 FY | -3.83 Million PLN | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bioceltix S.A. | -9.13 Million PLN | -532.245% |
| BIOTON S.A. | 64.81 Million PLN | 189.117% |
| Captor Therapeutics Spolka Akcyjna | -71.92 Million PLN | 19.699% |
| Mabion S.A. | -11.98 Million PLN | -381.75% |
| Molecure S.A. | -56.84 Million PLN | -1.598% |
| NanoGroup S.A. | -537.61 Thousand PLN | -10643.25% |
| Pharmena S.A. | -22.05 Million PLN | -161.865% |
| Pure Biologics Spólka Akcyjna | 9.33 Million PLN | 718.913% |
| Ryvu Therapeutics S.A. | -57.03 Million PLN | -1.269% |
| Synthaverse S.A. | 67.86 Million PLN | 185.102% |
| Urteste S.A. | -512 Thousand PLN | -11180.664% |